Novo Biosciences

Novo Biosciences is a private regenerative medicine biotechnology company spun out of MDI Biological Laboratory in Maine. The company is developing small-molecule therapies designed to activate endogenous repair mechanisms and regenerate damaged tissues, with an initial focus on cardiovascular and muscle diseases. Its lead program is trodusquemine (MSI-1436), a repurposed small molecule being advanced for acute myocardial infarction and also explored for Duchenne muscular dystrophy and other regenerative applications. Publicly available information indicates the company remains private and active, with grant and venture backing, but it does not appear to have disclosed a broad clinical-stage pipeline. Novo Biosciences is best characterized as an early-stage platform-oriented biotech focused on regenerative pharmacology.